Myostatin · Growth Differentiation Factor 8
GDF-8 (Growth Differentiation Factor 8), also known as Myostatin, is the biological molecule that NEGATIVELY regulates skeletal muscle growth. It is a member of the TGF-β superfamily, secreted by skeletal muscle cells, and acts in an autocrine/paracrine fashion to suppress muscle protein synthesis and limit muscle hypertrophy. Genetic loss-of-function in myostatin produces dramatic muscle hypertrophy (Belgian Blue cattle, the well-known 'mighty mouse' transgenic mouse line, and rare human cases of myostatin-related muscular hypertrophy).
GDF-8 / Myostatin is the muscle-INHIBITING factor itself. This entry is provided for catalog completeness. Users seeking muscle hypertrophy should use myostatin INHIBITORS (Follistatin 344, ACE-031, anti-myostatin antibodies in clinical trials) rather than administering myostatin itself.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
GDF-8 / Myostatin binds activin receptor type IIB (ActRIIB) on skeletal muscle cells, then recruits ALK4 / ALK5 type I receptors to form an active receptor complex. Receptor activation triggers Smad2/Smad3 phosphorylation and nuclear translocation, suppressing transcription of muscle hypertrophy genes (MyoD, myogenin) and activating muscle atrophy programs (FoxO-driven ubiquitin ligase expression).
Genetic myostatin knockout produces 2-3x muscle mass increase in mice; Belgian Blue cattle homozygous for myostatin loss-of-function have characteristic 'double-muscled' phenotype. Established as the dominant negative regulator of skeletal muscle mass.
Myostatin shares receptors with related TGF-β family members (activin A, GDF-11). Therapeutic inhibitors that target ActRIIB (e.g. ACE-031) capture multiple ligands simultaneously, which produces broader effects than myostatin-specific inhibition (and broader off-target potential).
Smad2/3 nuclear translocation suppresses MyoD/myogenin transcription, blocking myoblast differentiation and limiting hypertrophy under loading stress.
Beyond suppressing growth, myostatin also activates FoxO1/3-mediated transcription of atrogenes (MuRF1, atrogin-1) that drive muscle protein degradation - active atrophy signal at high concentrations.
Therapeutic strategies INHIBIT myostatin via: (a) soluble receptor decoys (ACE-031, BMS-986089), (b) anti-myostatin antibodies (domagrozumab, landogrozumab, trevogrumab, taldefgrobep), (c) follistatin (endogenous antagonist binding myostatin and other ligands), (d) propeptide-based inhibitors. None of these have achieved FDA approval as of this writing.
Administering exogenous GDF-8 / myostatin would SUPPRESS muscle growth - opposite of typical fitness/recovery use of peptides. This entry exists for catalog completeness; intentional administration is contradictory to typical user goals.
Reference protein - timeline does not apply to therapeutic context.
N/A
N/A
Each reference below was re-fetched from its PubMed record, and the quoted sentence was confirmed to appear in that abstract and to support the claim it sits under. Follow any of them to read the source.
GDF-8 is a negative regulator of skeletal-muscle growth.
These results suggest that GDF-8 functions specifically as a negative regulator of skeletal muscle growth.
Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member.
Evidence scope. Foundational gene-targeted mouse study; not exogenous human administration.
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.
Dose/route: not typically administered. No human therapeutic-administration abstract exists.
Full ActRIIB/Smad/FoxO cascade. The checked abstract did not state it.
Theoretical exogenous safety. No human administration abstract established it.
Endogenous myostatin half-life ~1 hour plasma; reference protein PK depends on formulation
Variable per formulation
Hours - reference protein only
Limited reference data - not typically administered
N/A - reference protein only
Hepatic / renal proteolysis
Storage. If encountered as a reference protein: refrigerate (2-8°C / 36-46°F) or freeze (-20°C). Lyophilized form is more stable than reconstituted. Reconstituted protein typically usable for 7-14 days refrigerated. Reference proteins should be handled per manufacturer's certificate of analysis specifications. Avoid freeze-thaw cycles.
GDF-8 / Myostatin itself has no FDA-approved therapeutic use. It is sold as a reference / research protein for laboratory use (assay standards for myostatin inhibitor development, ELISA controls, etc.) but not for human administration. Therapeutic development in this pathway focuses on INHIBITION of myostatin via various antagonist strategies. WADA's class S2 / muscle-modulator section indirectly relates to this molecule's biology but the prohibition targets myostatin INHIBITORS rather than the protein itself.
Put it to work
Open GDF-8 (Myostatin) straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open GDF-8 (Myostatin) in the app →Go deeper
The complete GDF-8 (Myostatin) walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗Track it in OnePin. Log vials, draws, and protocols in the app.
Type a name, brand, or tool. Esc closes.